Patient groups were well matched for demographic and disease characteristics , including region ( 60 % from Europe ) , HBV genotype ( 45 % genotype D ) , HBeAg status ( 47 % HBeAg-positive ) , and duration of lamivudine treatment ( mean , 3.8 years ) .